Literature DB >> 3395351

High dose methotrexate therapy: insecure rationale?

B A Kamen1, N J Winick.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3395351     DOI: 10.1016/0006-2952(88)90032-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  5 in total

Review 1.  Review of canine transmissible venereal sarcoma.

Authors:  U Das; A K Das
Journal:  Vet Res Commun       Date:  2000-12       Impact factor: 2.459

Review 2.  Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes.

Authors:  E Masson; W C Zamboni
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

3.  Red blood cell methotrexate and folate levels in children with acute lymphoblastic leukemia undergoing therapy: a Pediatric Oncology Group pilot study.

Authors:  M L Graham; J J Shuster; B A Kamen; D L Cheo; M P Harrison; B G Leventhal; D J Pullen; V M Whitehead
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.

Authors:  E Masson; M V Relling; T W Synold; Q Liu; J D Schuetz; J T Sandlund; C H Pui; W E Evans
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

5.  Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.

Authors:  T W Synold; M V Relling; J M Boyett; G K Rivera; J T Sandlund; H Mahmoud; W M Crist; C H Pui; W E Evans
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.